Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 11/20 | 0.56 |
| ▸ | DCLK1 | O15075 | 10/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | PIK3C2G | O75747 | 3/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 3/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.45 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.45 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094145 | 0.85 | LRRK2 (0.50) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL20094162 | 0.85 | MAPK7 (0.51) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL25357908 | 0.84 | DCLK1 (0.52) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL30526068 | 0.84 | DCLK1 (0.52) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL17721092 | 0.84 | MAPK7 (0.57) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL10098766 | 0.83 | DCLK1 (0.58) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL19457452 | 0.82 | PIK3CD (0.56) | MAPK7LRRK2PIK3CDAURKAPIK3C2G | |
| SCHEMBL30131807 | 0.82 | PIK3CD (0.56) | MAPK7LRRK2PIK3CDAURKAPIK3C2G | |
| SCHEMBL16065726 | 0.81 | MAPK7 (0.54) | MAPK7DCLK1LRRK2PIK3CDAURKA | |
| SCHEMBL20094197 | 0.81 | DCLK1 (0.53) | MAPK7DCLK1LRRK2PIK3CDAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116375713-B | DCLK1 protein degradation targeting chimeric and application thereof | 中国人民解放军海军军医大学 | 2024-11-19 | — | — | CN | disclosed |
| EP-3528814-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-114478539-B | Novel DCLK1 inhibitor and preparation method and application thereof | 中国人民解放军海军军医大学 | 2024-02-02 | — | — | CN | disclosed |
| EP-4229061-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| EP-3256470-B1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA FARBER CANCER INST INC (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116375713-A | DCLK1 protein degradation targeting chimeric and application thereof | 中国人民解放军海军军医大学 | 2023-07-04 | — | — | CN | disclosed |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| WO-2016022902-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2014160430-A1 | SMALL MOLECULE LRRK2 AND ERK5 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2014-10-02 | — | — | WO | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010080712-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | MAPK7 263/4885DCLK1 480/4885LRRK2 364/4885 |
| US-11583586-B2 | Methods to induce targeted protein degradation through bifunctional molecules | CRBN, MDM2, MYCBP | MAPK7 3496/4885DCLK1 1829/4885LRRK2 1253/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | MAPK7 253/4885DCLK1 453/4885LRRK2 340/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | MAPK7 4605/4885DCLK1 2364/4885LRRK2 1995/4885 |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMC2, PSMA6 | MAPK7 1599/4885DCLK1 2928/4885LRRK2 1277/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | MAPK7 3496/4885DCLK1 1829/4885LRRK2 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.